Video yükleniyor...
Video Yüklenemedi
#HDRanalysis. RCA CTO at proximal stent edge very close to ostium. Guide support was challenging. Tough proximal cap. Gaia 3rd, CP 12 failed. #HDR tried but failed. Cap punctured with Gaia 2nd. #HDR again. Pilot 200 crossed MC failed. 1.0, 2.5,3,3🎈 Acceptable final results.
11,419 görüntüleme • 8 ay önce •via X (Twitter)
0 Yorum
Yorum bulunmuyor
Orijinal gönderinin yorumları burada görünecek
![[Part 10] The side of Taehyung hyung's determination to never give up on his goal: Even with foot injury *the person received permissions to post* 👤In military bootcamp, there is something called a physical fitness test that is held every 2 weeks. The physical fitness test consists of 3 rounds, with the third round results being officially logged into the system. I am from a fitness background and so push ups and sit ups were very easy for me. But the running was a problem. The running category is for 3km. I got 2nd grade in the first round and 1st grade in the second round. To get Special Grade, you have to finish within 12 mins and 30 secs. For Elite Trainee eligibility, you must rank Grade 1 or above, which is below 13 mins and 20 secs. So although many people tried, most of them failed due to the running portion. Taehyungie hyung also kept getting Grade 2 in both the first and second rounds. He needed Grade 1, but his stamina but his stamina wasn't keeping up. That time he tols me, "I thought my stamina is great because I've been dancing for more than 10 years, but it hit me pretty hard to find it isn't like that." That's because Taehyungie hyung had a problem on his soles of his feet. There was even one time when his feet hurt so much that he couldn't keep running. However, in the final test even with his feet hurting so much, he managed to finish in Grade 1. So he said, whenever he ran, he could feel a shooting pain from his feet. So seeing him continue to run despite the pain in his feet was extremely impressive. (](https://image.24vids.com/tw-2060591789594247623/amplify_video_thumb/2060591730576244736/img/ne9VbWH6-RoOtkR9.jpg)
![Thabo Cele and Lebo Maboe double pivot vs Polokwane City📝 The level of organisation, discipline, and resistance was completely different compared to our games vs Magesi, Orbit or TS Galaxy and that matters when analyzing performance. And, before even getting into the Maboe–Cele double pivot, it’s important to address the front 3. Trying to impose a possession-based approach with Lilepo, Duba, and Silva is, at this stage, a bit unrealistic. The profiles don’t naturally support sustained control or efficiency in tight spaces; they are more direct, which makes the approach look slightly disconnected. Otherwise, who should combine with the double pivot to keep possession against a low block cos you're not inverting any fullbacks or CBs? Mdu[10] is also direct and won’t drop deep into ball circulation. ■ The midfield pairing of Cele & Maboe gave the team a clear structural balance in the 1st and 2nd phase, even if the chemistry is still far off. I mean, it's their 1st start together so🤷🏾♂️ Cele operated as a holding midfielder, anchoring the team behind/next to Maboe. He took on most of the defensive responsibility, well-positioned to screen the backline, and effective in managing transitions. ■ In possession, Cele was central to the 1st and 2nd phase of progression. He completed more passes than Plk City’s midfield duo of Kambala and Maphangule combined while also neutralising their 10 Mutudza. Mutudza managed just 5 passes in 66 minutes, which says everything about Cele’s dominance in that zone. He constantly made himself available in front of the CBs, scanning, managing the tempo, and organising the team’s structure. He always demanded movement from his teammates, always pointing to open spaces they should be occupying to progress better. At one point, he was calling Mdu to receive while Mdu was instead making a forward run away from Cele who had the ball. Cele didn’t force progression unnecessarily, but that doesn’t mean he lacked intent to move the team forward. He completed more line breaking passes and passes into the final 3rd than any other player. That highlights his awareness of when to accelerate play and when to maintain control. ■ Maboe, on the other hand, operated as the 8, with freedom to impact higher zones. With Cele securing the base, he was free to connect phases and influence play closer to the final 3rd. However, you could still see old habits from his previous role. He often dropped deeper than expected, which slightly limited his presence in decisive attacking areas. As much as he played balls into the final 3rd, we also needed him to receive in the final 3rd more. ■ Together, Cele and Maboe created 5 chances against a very disciplined low block of Plk City. 4 of those came from Maboe, underlining how much creative responsibility he still carried. However, this wasn’t his sharpest attacking performance in terms of passing and shooting. Despite the output in chances created, there were several misplaced passes in key moments, and he didn’t attack the box enough for an 8 with a reliable 6 behind him. It’s a similar issue we had with Mdu yesterday, he also struggled to consistently enter the opposition box as usual or combine between the lines. There was a clear lack of chemistry in the final 3rd in our overall performance. We couldn't stay on the ball enough to put pressure on their defense and cause enough panic for them to crack. ■ Towards midway through the 2nd Half, both Cele & Maboe started to lose some steam, and the pairing needed refreshing. At this point, Plk City had already overloaded the middle and allowed very little space for us to operate. We failed the same way in the loss vs Stellies, they improved their midfield to cancel our dominance, and we looked confused with our subs, no clear intention to improve a clear area that's been neutralized. Our struggles were not in the double pivot. There was nothing result-altering or structurally wrong with Maboe & Cele. [Video] Part 1:](https://image.24vids.com/tw-2045887731700559891/ext_tw_video_thumb/2045887060720885760/pu/img/e0-wMqe9a8wsJnU7.jpg)
![The Alleged Secret Conference Call [alleged] At 1:34 a.m. on Thursday morning, Christmas Day, while markets were closed, six powerful figures in global finance reportedly held a 47-minute conference call. The participants included the Global Head of Commodities at JPMorgan, the Head of Derivatives Trading at HSBC, the CEO of the CME Group, a senior U.S. Treasury official, the representative for the Bank for International Settlements, and the chairman of the London Bullion Market Association. No official record or press release was made. The narrator claims a source on the call sent a message at 3:15 a.m. saying simply, “They agreed $75.” This was described as an emergency summit to prevent silver from crossing $75, a price level allegedly capable of triggering systemic collapse due to massive exposures in call options. $75 Is the Critical Line There are said to be 41,000 open call option contracts at the $75 strike price, expiring in January 2026, representing 205 million ounces of total exposure. Banks reportedly sold these options when silver was around $50, collecting premiums without proper hedging. At prices around $71-72, the banks remain comfortably hedged. However, if silver breaks and holds above $75 for more than 48 hours, delta hedging requirements would explode, potentially requiring 180 to 200 million ounces. With COMEX registered inventory at only about 24.8 million ounces, London withdrawals restricted, and ETFs frozen, delivery would become impossible, leading to price gaps toward $80, $85, and then $100 in a death spiral. The alleged agreement - a gentleman’s deal for coordinated selling to maintain a ceiling at $75, with regulatory cover and unlimited liquidity backstop from the BIS. What Happened on the Call The call was scheduled at 1:34 a.m. Eastern Time to avoid detection. The CME CEO reportedly opened by saying silver was refusing to stay down—they had smashed it to $70.16 earlier, but buyers rallied it back to $71.69, leaving it only $3.31 from the $75 strike. Volatility was too high, and a snap to $75 would force buying of 180 million ounces they could not deliver. A hard ceiling at $75 was needed. The JPMorgan executive spoke next, noting they were short about 35% of the contracts and already bleeding at $71.69, facing potential $500 million losses in 24 hours if $75 was breached. Coordinated action was essential. The Treasury official sounded urgent, viewing $100 silver as a macro threat signaling loss of confidence in the dollar, and offered support for stabilization efforts within legal parameters—interpreted by the narrator as permission to do whatever was needed. The deal involved coordinated selling whenever silver approached $73, political pressure on ETFs to halt buying, and unlimited dollar liquidity from the BIS for any bank in trouble. The call ended around 2:21 a.m. The Cap in Action On Wednesday, December 24, Christmas Eve, silver reached a high of $72.75 before a midnight dump crashed it to $70.16 in an attempt to break $70 support and induce panic. Physical buyers stepped in, rallying it back to close around $71.69. The narrator calls this a failed execution of the alleged plan, not random volatility. With markets reopening on Friday, December 26, a coordinated media campaign was expected, with experts claiming silver was overbought and demand slowing to discourage holders. Why the Cap Will Fail Banks can coordinate paper selling and print dollars, but they cannot create physical silver. There is a real 1.1 billion ounce annual deficit, refineries remain constrained, and crucially, Shanghai buyers are bidding massive premiums, purchasing physical at equivalent prices around $80 while dismissing paper games. As long as this arbitrage persists, physical will drain paper dry. JPMorgan, HSBC, and Scotia Mocatta pretending to cooperate, but bankers follow a prisoner’s dilemma. All are heavily short and losing money. If one covers, the price skyrockets, bankrupting the others](https://image.24vids.com/tw-2004563791166451719/amplify_video_thumb/2004563458830864384/img/zBcFa4sHDCZHpHVt.jpg)
![An interview by VERY DARK AND CORRUPT Wall Street Journal aired today [1] WSJ's terrible "journalists" (and I use that term lightly) made many false statements about Sarepta's worthless, dangerous drug and Vinay Prasad's firing [1,2] I explain how the FDA sausage is made in excruciating detail Buckle up To get readers up to speed -> In June, corrupt pharma company Sarepta Therapeutics paid $40,000 to lobbying group Michael Best Strategies (MBS) to deal with a problem [3] -> MBS had recently hired Chris LaCivita, who had close connections with "MAGA" influencer Laura Loomer [4] -> With stock down 88%, Sarepta needed to sell their very bad, very dangerous drug or the company would go bankrupt [5] -> After several deaths from the drug this year, FDA official Vinay Prasad said "no way" and kicked the drug to the curb [2,6] -> Sarepta panicked and paid MBS (we believe) to deal with Prasad [3,4] -> If this story is right, LaCivita recruited Laura Loomer to take down Prasad [4,7] -> Loomer said she was defending Trump, but she was lying [7] -> She was defending taxpayer-funded payouts to a worthless, corrupt company [7] -> Laura Loomer so brave A history of bad drugs and regulatory failure -> This is one of the worst pharma scandals in American history and corrupt mainstream media isn't covering it -> Sarepta has a very long, troubled history [8] -> For more than a decade, every major Sarepta FDA drug approval has required INTENSE political intervention [8,9] -> Scientists at FDA have been repeatedly overruled [8,9] -> Many scientists have resigned, very publicly, over these POLITICAL decisions, some writing scathing public criticisms of these terrible decisions [10,11] -> The most recent resignation by Vinay Prasad is not something new; it follows in a long tradition [2,10] -> In fact, standards have dramatically deteriorated since the first controversies about the company's drugs in the 2010s [8,9] -> Prasad was trying to hold the line in the face of rapidly deteriorating standards at the agency [2,6] -> For that, pharma launched a coup--a literal coup of a drug regulator [4,6] -> This is unprecedented -> Banana republic sht, unbelievably corrupt 2016: first Sarepta drug approval and the "highly unusual" decision -> The first Sarepta drug approved by FDA was called Exondys 51 [8] -> This drug was for patients with mutations in dystrophin, a muscle protein [8] -> This is a debilitating and fatal disease affecting children [8] -> Exondys 51 increased dystrophin by 0.2% of normal levels [8,12] -> Unsurprisingly, there was no good evidence the drug worked [8,12] -> Why would it? It increases the protein from zero to 1/500th of normal levels -> One reviewer wrote: "I can find no precedent of an accelerated approval for a marketing application where the effect size on the surrogate endpoint is as small as 0.3%." [12] -> The study submitted by the company included no proper control group [12] -> The techniques used were so bad not even a first-year PhD student would do a study that way -> This the level of work you would expect from a mediocre undergraduate with no guidance -> It's almost like it was so bad on purpose -> (Narrator: it was on purpose) -> Nerd time: -> One reviewer wrote: "The Western blots submitted by the applicant for Study 201 were oversaturated, unreliable, and uninterpretable." [12] -> Another wrote: "Because CDER also determined that the conditions under which the original IHC analysis was performed were inadequate, including that the reader was not masked to sequence and time, the Center requested a re-reading of the stored images by three masked pathologists under different conditions. The IHC results from the reread were not nearly as favorable, as compared to the initial IHC results reported by Sarepta." [12] -> "The lack of concordance between the IHC and the Western Blot results is 'striking'" [12] -> "Study 201/202 had fundamental flaws, including baseline biopsies from external controls who could differ in unknown ways from study subjects, Week 180 biopsies from different muscles than baseline, and potential protein degradation in stored baseline samples." [12] -> And on and on. -> FDA commissioner Robert Califf wrote at the time: the submitted study was "characterized by major flaws in the clinical study design" and "Blinded experts assembled by the FDA fundamentally debunked this study, which has yet to be retracted and continues to be cited" [9,12] -> That's right, the FDA commissioner expressed dismay that the study that the company used to gain approval hadn't yet been retracted, it was so bad [9] -> Senior FDA official Janet Woodcock decided to approve before scientific review team had even voted [9,12] -> Woodcock be like: yeah i'm going to decide before you guys can because i know what you're going to say lol -> Despite external intense pressure, FDA scientists voted against Exondys 51's efficacy [9,12] -> They then voted against its accelerated approval [9,12] -> The review team filed an appeal with FDA commissioner after "passionate" disagreement with Woodcock [9,12] -> One reviewer called Woodcock's decision "unprecedented" [12] -> In a 126-page report, FDA commissioner Califf called Woodcock's decision "highly unusual" [9] -> The FDA board wrote: "[Woodcock's] involvement here appears to have upended the typical review and decision-making process. ... Care should be taken to avoid the appearance of interfering with the integrity of scientific reviews at the lower levels of a Center." [9] -> Again, the data were unbelievably bad, literally every technique in the study was inappropriately used [12] -> I would fire an undergraduate student who did science like this, immediately -> FDA's chief scientist accused Sarepta of "serious irresponsibility" for selectively publishing only some of the data [9] -> Even Woodcock, who approved the drug, called the research "seriously deficient" [12] -> Yes, even the person who approved the drug over the heads of FDA's scientists said the research was horrible [12] -> Still, FDA tried to bury their heads in the sand and beg that, basically, Sarepta pretty please do a better job next time -> FDA commissioner: "The utmost attention should be paid to optimizing the methodological rigor of [future] trial[s]" [9] -> FDA also demanded a clinical trial "to verify the benefit" of the drug [8] -> Welp, this was in 2016 [8] -> The trial results are supposed to be available in 2026, maybe [13] -> Or maybe later, depending on how much money needs to be made first -> As an article published in Nature three years later despaired of the decision: "The approval was conditional on the company agreeing to conduct a two-year post-approval trial to show Exondys 51’s efficacy. But by August 2019, the company had yet to begin such a trial and in the meantime had profited from sales of $300 million in 2018." [13] -> If it sounds like Sarepta used political pressure to get its drug approved and then tried to avoid actually publishing the study showing it didn't work, it sounds that way because that's exactly what happened [13] -> FDA commissioner after deferring to Woodcock: "I am confident this unique situation will not set a general precedent for drug approvals under the accelerated approval pathway, as the statute and regulations are clear each situation must be evaluated on its own merits based on the totality of data and information." [9] -> This statement was profoundly naive, and the historical record bears this out [8,14] -> Three FDA scientists resigned, including the lead reviewer of the drug, understanding the grave implications of the collapse of scientific standards and where they would lead [10,11] -> One was John K. Jenkins, M.D. Director, Office of New Drugs Center for Drug Evaluation and Research/FDA [10] -> In a presentation given just before his resignation, he wrote: -> "Path taken by Sarepta NOT a good model for other development programs" [10] -> Crucially: -> "Upholding statutory standards for approval in face of hopes and desires of patients, families, sponsors, and investors is a very difficult job" [10] -> "Personal attacks on FDA reviewers creates an atmosphere of distrust and isolation rather than collaboration" [10] This brings us to WHY Sarepta's drug was approved Facebook FDA -> So why did the drug get approved? -> Basically, Sarepta propagandized extremely desperate patients [9,15] -> They used miraculous snake oil promises and patients believed them -> Remember that this is life or death for patients, and they are extremely vulnerable -> Sarepta also professionally trained some patients to give testimonials to FDA and congress [15] -> The patients then went to congressmen who don't have time to understand the science [15] -> They gave emotional stories to congressmen [15] -> The result: -> Letter from 109 House members [15] -> Letter from 24 Senate members [15] -> And a media circus documented in the New York Times [16] -> Patients screaming at scientists during meetings [9] -> 2,792 emails written to FDA urging approval [12] -> One of them: "Dear Dr. califf: How is it that everyone in and around DMD understands this simple Idea and the science geniuses at FDA don't? You stupid fckers are costing each and every DMD kids days of their lives with your Moronic Dystrophin dance. Time to get a fcking clue" [12] -> Upon approval, a journalist for Reuters wrote: "owing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy" [17] -> A commentary in Nature Medicine was also published called "Railroading at the FDA" [9] -> Its author wrote: "In the words of one FDA committee member, Exondys lowers the agency's evidentiary standard for drug effectiveness 'to an unprecedented nadir.'" [9] -> A highly critical commentary was also published in Science, titled "Sarepta gets an approval - Unfortunately" [18] -> The article's author pharma veteran Derek Lowe wrote: "The company... called up Duchenne-affected boys and their families to plead with the FDA, and won over Janet Woodcock, and that appears to be enough. Is this going to be the new way to get a drug approved? Run a trial in a dozen people, generate unconvincing data, and then lobby Janet Woodcock? I share the worries that this might open the floodgates, because after all, Sarepta got their drug through." [18] -> One FDA reviewer ended in an equally grim note: ". Approval of this NDA would send the signal that political pressure and even intimidation – not science – guides FDA decisions, with extremely negative consequences. The public is well aware of this development program: the meager size of the study population, the marginal (at best) effect size, the Division’s dim view of the efficacy data, and the robust activism of some members of the DMD community. Many would be amazed at an approval action, because other DMD drugs, recently turned down for approval, appeared to provide stronger evidence of efficacy. ...The ramifications here are profound. The public will perceive that it was their unprecedented lobbying efforts that made the difference and earned eteplirsen its accelerated approval. For the future, this will have the effect of strongly encouraging public activism and intimidation as a substitute for data, which is one of the worst possible consequences for communities with rare diseases. This type of activism is not what was envisioned for patient-focused drug development." [12] -> A new era was born -> Activism had replaced data -> Facebook had fried people's brains -> And now Facebook-fried brains had fried FDA too -> FDA's credibility as a regulatory agency would now be hollowed out -> FDA's Facebook age had begun -> But the worst was yet to come Sarepta approvals: 2016 to present -> Three more drugs were approved from Sarepta on the same shoddy basis, proving Califf's promises that Exondys 51 was an isolated case empty [8,14] -> But things would take a turn for the worse with Sarepta's newest drug Elevidys in 2024 [19] -> At last a rigorous clinical trial looking at actual clinical outcomes was published [19,20] -> All would be put to rest -> At long last the issue could be resolved with HARD CLINICAL DATA -> There was only one problem -> The trial failed to show any benefit according to the primary outcome [19,20] -> The surrogate biomarker of micro-dystrophin meant absolutely nothing; it wasn't actually helping patients [19,20] -> What did FDA scientists do? They voted against approval. Of course [19] -> How could they not? The drug didn't actually work in the clinical trial [19] -> It's the only thing that made sense, since FDA is a scientific agency -> AND THEY WERE OVERRULED AGAIN BY PETER MARKS [19] -> YES THAT'S RIGHT, OVERRULED YET AGAIN -> PHARMA WINS AGAIN -> HAHAHAHAHAHA PHARMA ALWAYS WINS YOU FOOLS -> What happened is that Marks crossed his eyes somewhat, trying to make the words on the page blurry -> He prayed really hard, "my god please give me a sign, something, anything, I need this for my career" -> lzzosolsolzzolzozlslzolosllslozllzlzl -> Marks was trying really hard to see SOMETHING, come on come on, give me SOMETHIGN he said -> And he said: wait, look, there are these secondary, exploratory endpoints and a two of them look pretty good, I'LL APPROVE [19,20] -> AHAHAHHAHAHA YES PHAMRA WINS AGAIN -> And Marks said, "Thank you pharma go- I mean god, not pharma god, why did I just say that, FCK" -> The trial was explicitly designed for what Marks did NOT to happen [20] -> Once the primary endpoint was not met, the secondary endpoints couldn't even be statistically tested [20] -> And the trial explicitly said that they could not be interpreted the way Marks interpreted them [20] -> They were not adjusted for multiplicity and they were, like expression of dystrophin, simply bad endpoints [20] -> These two secondary endpoints were time to rise from lying on the floor and the 10-meter walk/run tests [20] -> Subjects who received the Elevidys performed, on average, about 0.5 seconds better than placebo recipients on these tasks [20] -> However several facts must be borne in mind when interpreting these: -> 1. At the time of testing, patients receiving the drug were receiving more corticosteroids than placebo patients, biasing the results [20] -> 2. Blinding might have been broken because those receiving the drug experienced lots of nausea and vomiting from the drug (~70%) [20] -> 3. These differences were tiny and may be attributable to chance, since the natural course of the disease varies widely [20] -> Marks knows this but who cares? Pharma I mean Facebook needed to be placated Elevidys: the drug -> To understand why this is so messed up, one must understand a few things -> On a Bayesian basis, one must assume that Elevidys is harmful until proven otherwise, for two reasons: -> 1. All drugs are potentially "toxic", but some toxins heal: by default you must assume it is a toxin that does not heal because this is what is actually usually the case; you need evidence that it actually heals -> 2. Elevidys IN PARTICULAR must be assumed to be harmful until proven otherwise because of the very nature of the drug -> Let's do a breakdown of the basic science of Elevidys that supports this (Bayesian) hypothesis: -> Gene therapy that permanently integrates into human genome [21] -> Meant to replace dystrophin, the protein that these patients cannot produce themselves [21] -> Preferentially targets muscle but gets expressed everywhere [21] -> Killed three people this year [6,21] -> Costs $3.2 million per injection [21] -> Truncated version of the protein it is supposed to replace [21] -> 3X shorter than the real protein [21] -> Has to be truncated because the technology cannot create the full protein [21] -> Because it's an abnormal protein, it's foreign, so immune system attacks it [21] -> Patients injected with drug are basically given an autoimmune disease [21] -> Patients have to be given anti-inflammatories to fight the disease that the drug causes [21] -> Causes terrible muscle inflammation [21] -> Inflames the heart, heart walls thicken because of the inflammation [21] -> Blows up the liver, causes acute liver injury and death [21] Drug should actually be assumed harmful, not beneficial -> Given all of the above, since the drug failed to meet its primary endpoint, it should actually be considered harmful by default, not beneficial [19,20] -> In other words, what we would actually expect if we added more patients and did an even larger study... -> Is that the drug would do worse than placebo, i.e., patients taking the drug would do worse than those taking placebo -> Why isn't this the default interpretation? -> They are reading the study with an intervention bias -> An intervention bias is natural, which is why "do no harm" is such a central tenet of medicine -> If I may put forward a thesis: most of Vinay Prasad's 500+-paper body of work has been dedicated to demonstrating the "do no harm" principle empirically [22] -> Rose-colored glasses study interpreters are simply not applying this principle properly and are thus failing scientifically in the most fundamental way -> Incomprehensible -> Back in 2016, scientists were adamant that the approval of Sarepta's first drug indicated the profound deterioration of scientific standards [8,9] -> But this latest approval is even worse: actual clinical data is now being overruled -> No standards at all are being enforced anymore; anything can now be approved based on any evidence whatsoever -> What Vinay was trying to do was simply to stop the unrelenting downslide -> And his firing punctuated that downslide for what it was The WSJ segment -> When Elevidys was approved, former FDA chief scientist and one of the original reviewers of Sarepta's first drug Luciana Borio said: -> "I don’t know what to say. Peter Marks makes a mockery of scientific reasoning and approval standards that have served patients well over decades. This type of action also promotes the growing mistrust in scientific institutions like the FDA." [23] -> To return to this video, these two WSJ reporters show an incredible level of ignorance and arrogance -> Finley says that the drug is "clearly" beneficial by misreading the secondary endpoints, just like Marks did -> An FDA memo from last year says about these endpoints: "Under these circumstances, they are misleading and cannot guide any stakeholders—including patients, family members and caregivers, and prescribers—in making informed decisions about the potential benefit of treatment with ELEVIDYS." [20] -> It really doesn't get any clearer than that -> But these two journalists are overruling the actual scientists, just like Marks did -> One of the most incredible comments during this interview was the complaint that "90% of clinical trials fail", as if that's bad thing [1] -> It's actually a good thing; most drugs suck; failing in clinical trial actually allows us to use only the drugs that don't suck -> These people don't understand the most fundamental purpose of the clinical trial -> They think clinical trials failing is a bad thing, as if it means that patients now won't get to use a useful drug -> No, it's a good thing, because it means that patients won't be exposed unnecessarily to a useless drug that might harm them -> The level of ignorance really is unbelievable -> What's worse is that these "journalists" defend their decision -> But what they did is exploit social media hysteria caused by Laura Loomer [1,7] -> Following up on her heels with editorials, using her as pharma attack dog [1,4] -> This is a huge blow to WSJ's credibility, and they know it -> Unbelievably shameful Where do we go from here? -> The Vinay Prasad firing creates a serious crisis of credibility at FDA [2,6] -> Up to this point, we could call these approvals a difference of opinion, but as we've seen, that's a huge stretch -> But any illusion of that is now shattered: the firing shows that drug regulation is explicitly political -> Janet Woodcock: approve, keep job -> Peter Marks: approve, keep job -> Vinay Prasad: block, transparently fired -> Make a decision that is anti-pharma and lose your job: that's the message -> Who can trust any decision at FDA anymore? -> RFK Jr. and Marty Makary both stand behind Vinay Prasad [24] -> Trump went along with lockdowns, he went along with mask mandates, he went along with all of the Covid pseudoscience that he now decries -> He should reverse course and not go along with this -> Trump has created a profound crisis of credibility at FDA and needs to fix it](https://image.24vids.com/tw-1952294845248114806/amplify_video_thumb/1952292444621451264/img/SPXp7ZpvQZ3FQV7_.jpg)
